Knowledge HQ

Development of BAFF ligand-based CAR-T cells targeting BAFF-R, BCMA, and TACI. Cells were modified using the TcBuster transposon system and maintained in G-Rex culture vessels.

This review discusses CAR structure and automated manufacturing platforms. It highlights the G-Rex (M series) and GatheRex pump as a practical, cost-effective, and scalable static culture option for CAR-T expansion.

The study demonstrates manufacturing of CD7 CAR T cells using ibrutinib/dasatinib to prevent fratricide. cGMP manufacturing involved transduction and expansion in G-Rex culture devices for 3 additional days.

This paper compares CIK cell expansion in G-Rex devices vs standard plates. G-Rex 24-well and 6-well plates were used. G-Rex resulted in significantly higher expansion and IFN-g secretion, supporting clinical-scale production.

This study describes the ADAPT-NK cell product derived from superdonors. The expansion protocol involved co-culturing CD3/CD19-depleted PBMCs with feeder cells in G-Rex 24 plates for 11 days to generate high numbers of adaptive NK cells.

The study identifies SIK3 as a gene protecting tumor cells from T-cell cytotoxicity. In the methods, TILs were rapidly expanded using a modified Rosenberg protocol involving culture in G-Rex 100 with feeder cells and IL-2.

The study outlines improvements to the manufacturing of MT-401 (multiTAA-specific T cells). The new process using G-Rex 10M and scaling to G-Rex 500M reduced duration to 9 days and improved T cell purity and memory phenotype.

This poster introduces the Go-Rex device, built on G-Rex technology, for long-term 3D tumor modeling. It allows assessment of T-cell migration, infiltration, and killing over extended periods compared to traditional assays.

The study compares TIL expansion methods. TIL 3.0 (IL-2 + anti-CD3 + anti-4-1BB) in G-Rex expanded more TILs with better CD8+ enrichment and TCR diversity than standard IL-2. The REP phase also used GREX-10M.

Describes a non-viral CRISPR/Cas9 method using ssCTS templates for high-yield CAR-T production. A GMP-compatible process was developed where cells were expanded in G-Rex 100M gas-permeable culture vessels for 7-10 days.

This paper explores combining radiotherapy with CD98hc-targeted UniCAR T cells for HNSCC. The combo showed synergistic anti-tumor effects. Genetically modified T cells were seeded in 24-well G-Rex plates and expanded for 4–6 days.

The study generates and validates allogeneic CD123 CAR-Delta One T (DOT) cells for AML. These cells showed potent cytotoxicity against AML lines and primary samples. DOT cells were generated from alpha-beta depleted PBMCs cultured in either 96-well plates or the G-REX platform.